Biota Pharmaceuticals Announces Changes to Its Board of Directors
ATLANTA, Aug. 19, 2013 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc.
(Nasdaq:BOTA) ("Biota" or the "Company"), a biopharmaceutical company focused
on the discovery and development of anti-infective products to prevent and
treat serious and potentially life-threatening infectious diseases, today
announced changes to its Board of Directors, including the resignation ofDr.
Jeffrey Errington, and the appointment of Mr. John P. Richard to fill the
vacancy created by Dr. Errington's resignation.
"On behalf of Biota, I want to express gratitude to Jeff for his contributions
to the board and Company over the past four years," said Dr. James Fox,
Chairman of Biota Pharmaceuticals, Inc.
Mr. Richard brings significant corporate, operational and transactional life
sciences experience, having served in various executive and director roles
during his career. Mr. Richard currently is a partner and director of two life
science focused venture capital firms, Phase4 Ventures and Georgia Venture
Partners, as well as a co-founder and interim CEO of QUE Oncology, Inc., an
Australian/U.S. joint venture focused on the discovery of novel oncology
drugs.He also serves as an advisor to Albireo AB and Nabriva Therapeutics AG,
both of which are life science companies,.His previous leadership roles
include, among others, Executive Vice President, Business Development of
SEQUUS Pharmaceuticals, Vice President of Corporate Development of VIVUS, and
Senior Vice President, Business Development at Genome Therapeutics
Corporation. Mr. Richard also currently serves as a non-executive director of
Targacept (Nasdaq:TRGT), Zosano Pharma, Altiris Therapeutics, Inc, and
"We are very pleased to welcome John to the Board," Dr. Fox added. "We expect
John's deep and diverse skill set and industry perspective will be beneficial
in the development and implementation of our growth strategy."
Biota Pharmaceuticals, Inc. is a biopharmaceutical company focused on the
discovery and development of products to prevent and treat serious and
potentially life-threatening infectious diseases. The Company currently has
two Phase 2 clinical-stage product candidates in development: Laninamivir
octanoate, which the Company is developing for the treatment of influenza A
and B infections in the U.S. through a contract with the U.S. Office of
Biomedical Advanced Research and Development Authority (BARDA) that provides
up to $231 million in financial support to complete its clinical development;
and vapendavir, a potent, oral broad spectrum capsid inhibitor of
enteroviruses, including human rhinovirus. In addition to these
clinical-stage programs, the Company has preclinical programs focused on
developing treatments for respiratory syncytial virus and gram-negative,
multi-drug resistant bacterial infections. For additional information about
the Company, please visit www.biotapharma.com.
Biota is a registered trademark of Biota Holdings Limited.
CONTACT: Russell H. Plumb
President and CEO
Biota Pharmaceuticals, Inc
Press spacebar to pause and continue. Press esc to stop.